Acetazolamide Market Size, Share, Sales, Analysis, Forecast, Industry Competition & Player Profiles 2023-2032

Acetazolamide is a carbonic anhydrase inhibitors which is used to reduce pressure in the eye in people with certain types of glaucoma. It is also sometimes used to treat epilepsy. The key factor driving growth of the global acetazolamide market is the rising demand for this product among patients suffering from glaucoma, which is the most common reason for permanent blindness worldwide. 

The global acetazolamide market is quite consolidated with limited number of manufacturers having strong foothold in key international markets. Key regions across the world such as China, Japan, India, and Europe are among the prominent consumers of acetazolamide.

The report titled “Global Acetazolamide Market – Competitive Portfolio, Market Share, Business Strategy, and Developments, 2023-2032” offers strategic visions into competitive landscape of the global acetazolamide market. The report would offer company overview for each leading player active in the global acetazolamide market while considering parameters namely global sales network, employee strength, key executives, listing on the stock exchange, subsidiaries, R&D activities, and manufacturing portfolio. For instance, the R&D spending for Teva Pharmaceutical Industries Ltd. was US$ 1.8 Billion in 2017 indicating strong focus on strengthening its market position. The global acetazolamide market revenue stood at US$ 190.3 Million in 2017 and is expected to expand at a CAGR of 5.1% from 2019 to 2024.

The report also covers business segment analysis which would enlist all the business segments of the company and would further identify the placement of the acetazolamide segment in the company’s overall portfolio. Furthermore, acetazolamide segment share in the total company business would also be highlighted. For instance, Lannett offers products for a number of medical conditions among which product share for Galucoma in the overall sales revenue was 2.96%. Lannett has strong presence in the U.S. with corporate offices in four states namely Pennsylvania, Indiana, New York, and Wyoming.

The report also covers key competitive information such as product portfolio and recent developments for all acetazolamide producers. Product portfolio encompasses all the available products under the acetazolamide business segment. The product details would include product name, specifications, commercial production date, and technology utilized in its production. Whereas, recent development section provides details into the latest development activities of the company. This section highlights developments such as product/technology expansion, acquisition, new product launches, geographical expansion, partnerships, alliances, and new investments into acetazolamide products. For instance, in November 2017, Strides Shasun Ltd. through its subsidiary Strides Pharma Global Pte. Ltd. announced that it has received approval from the United States Food & Drug Administration (USFDA) for Acetazolamide Tablets USP 125 mg and 250 mg, which are generic versions of Diamox Tablets®. Key players in the global acetazolamide market are strongly focusing on marketing acetazolamide drug for its strong benefits in treating various types of glaucoma.

The key players active in the global acetazolamide market include Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), eva Pharmaceutical Industries Ltd., Heritage Pharmaceuticals Inc., Lannett Company, Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd., Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.

Market Segmentation

By Geography

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America